Efficacy of single lead VDD pacing in patients with impaired and normal left ventricular function

Atrial synchronous ventricular pacing seems to be the best pacing mode for patients with advanced AV block and impaired LV function. The long-term follow-up of single lead VDD pacing was studied in 33 patients with impaired LV function and compared to 42 patients with normal LV function. All patients received the same VDD lead and VDDR pacemaker. The lead model with 13-cm AV spacing between the atrial and ventricular electrode was implanted in 89% of the patients. Follow-ups were 1, 3, 6, and 12 months after implantation. The percentage of atrial sensing and the P wave amplitude were determined at each follow-up. Minimal P wave amplitude at implantation was 2.0 +/- 1.4 mV in patients with impaired and 1.7 +/- 0.9 mV with normal LV function (not significant). At the 12-month follow-up, 33 patients with normal and 23 patients with depressed LV function remained paced in the VDD mode. The remaining patients died in five (impaired LV function) and seven cases (normal LV function) or their pacemakers were programmed to the VVI/VVIR pacing mode in four (impaired LV function) and three cases (normal LV function). P wave amplitude did not differ in the two groups (e.g., at month 12: impaired: 1.17 +/- 0.42 mV; normal: 1.09 +/- 0.49 mV). The atrial sensitivity was programmed in most patients to sensitive settings with no differences between the two groups (e.g., at month 12: impaired: 0.13 +/- 0.06 mV; normal: 0.13 +/- 0.05 mV). The diagnostic counters indicated nearly permanent atrial sensing (e.g., at month 12: impaired: 99.3 +/- 2.2%; normal: 99.0 +/- 1.0 mV). In conclusions, single lead VDD pacing restored AV synchronous ventricular pacing in patients with normal and with impaired LV function indicating that it could be an alternative to DDD pacemakers, but not to dual-chamber pacing.     

Recurrent atrial electrode displacement complicating a single lead VDD pacing system

We describe an unusual complication of single-lead VDD pacing: recurrent advancement of the atrial bipole into the right ventricle. As a consequence, the patient experienced symptomatic pacemaker-mediated tachycardia and underwent two revision operations to achieve adequate fixation of the lead.     

Three-year follow-up of atrial sensing efficacy in children and adults with a single lead VDD pacing system

The purpose of this study was to evaluate the efficacy of atrial sensing in children with a single pass lead VDD pacing system and to compare it with the efficacy of atrial sensing in adult patients with the same pacing system. Although the feasibility of single pass lead VDD pacing system implantation in children was recently demonstrated, the efficacy of atrial sensing remains unclear. In addition, the effect of accelerated growth of children on the systems' efficacy has not been addressed. Atrial sensing followed by ventricular sensing and atrial sensing followed by ventricular pacing was prospectively evaluated in 13 children (age 0.5-15 years) and 24 adult patients (age 19-74 years). All had the same endocardial pacing system using a single pass lead. The children and adults had effective atrial sensing at a success rate of 94.00 +/- 9.687% and 96.04 +/- 4.64%, respectively, during mean follow-up of 3.5 years. The atrial electrogram amplitude was similar in both groups, 1.8 +/- 1.5 mV in children and 1.8 +/- 1.1 mV in adults. The adult patients more frequently exhibited ventricular sensing following atrial sensing. The ventricular pacing threshold and impedance were stable in both groups. When necessary, in children, the atrial sensing was corrected by adjusting the pacemaker's lower rate programming. Highly effective atrial sensing was demonstrated in children and adult patients with a single pass lead VDD pacing system. During a mean follow-up of 3.5 years, not only was the atrial electrogram amplitude stable, but the clinically relevant atrial sensing was highly effective, justifying endocardial pacing with single pass lead VDD pacing in children and adults with preserved sinus node function.     

Evaluation of the early hemodynamic changes in carotid arteries during ventricular and dual chamber pacing

In spite of a wide choice of pacemakers, there are some problems in making more rational clinical decisions for individual patients since mode selection and programming is usually performed on the basis of a clinical hunch. The aim of this study was to measure the differences in carotid flow in patients with a pacemaker programmed in the dual chamber and in the single chamber pacing modes. Sixty patients with implanted bipolar DDD pacemakers were enrolled in this study. Blood peak systolic velocity (PSV) and end-diastolic velocity (EDV), cross-sectional area, resistive index (RI), and pulsatility index (PI) were measured in the common (CCA), internal (ICA), and external (ECA) carotid arteries before pacemaker implantation and after dual chamber and ventricular pacing at 60 beats/min. PSVs in the left CCA (79.3 +/- 24.9 cm/s) and right CCA (84.1 +/- 18.7) were shown to significantly decrease after VVI pacing (60.1 +/- 16.6 and 62.1 +/- 20.0, respectively). There was also a similar significant decrease in PSV in the left and right ICAs and ECAs. Besides PSV, RI, and PI in the left and right CCAs, ICAs, and ECAs significantly decreased after VVI pacing. There was no similar decrease after DDD pacing. Cross-sectional area and flow volume in the CCA, ICA, and ECA were similar after DDD and VVI pacing and before pacemaker implantation suggesting that cardiac output was similar when the measurements were recorded. Carotid artery PSVs, pulsatility, and RIs were found to be significantly decreased during VVI pacing compared to baseline and DDD pacing. The greater incidence of adverse cerebral outcomes in patients with VVI rather than DDD pacing may be partly due to decreased carotid PSVs.     

Clinical relevance of loss of atrial sensing in patients with single lead VDD pacemakers

During single lead VDD pacing, loss of atrial sensing is reported to be 2%-11% of patients in the literature. The impact on quality-of-life and exercise duration has never been established. This study tried to assess the clinical relevance of loss of atrial sensing in patients with single lead VDD pacemakers. Twenty-one patients with total AV block were studied 3 months after single lead VDD pacemaker implantation. During a 6-minute walk test, atrial undersensing was verified and adjusted to achieve undersensing in < 5% (group 1), 5%-10% (group 2), and > 10% (group 3). Patients were allocated to each group in a randomized double blind crossover design. At the end of each 2-month study period all patients underwent symptom limited treadmill exercise testing. Subjective assessment of exercise difficulty was made using the Borg score, and quality-of-life assessment was performed using the Health Status Questionnaire. Exercise duration significantly decreased in group 3 (228 +/- 50 s) as compared to group 1 (257 +/- 42 s) and group 2 (250 +/- 46 sec) with an increase in the Borg score. Quality-of-life was decreased for three subscales in group 3 as compared to group 1 and group 2. In conclusion, atrial undersensing of > 10% in patients with single lead VDD pacing was associated with a decrease in exercise duration and increase in the subjective severity score, in addition to a decrease in quality-of-life. Atrial undersensing of < 10% did not effect exercise test results or quality-of-life. Since all studies reported intact atrioventricular synchrony in > or = 90% of patients, loss of atrial sensing is of limited clinical importance in these patients.     

European clinical experience with a dual chamber single pass sensing and pacing defibrillation lead

Dual chamber ICDs are increasingly implanted nowadays, mainly to improve discrimination between supraventricular and ventricular arrhythmias but also to maintain AV synchrony in patients with bradycardia. The aim of this study was to investigate a new single pass right ventricular defibrillation lead capable of true bipolar sensing and pacing in the right atrium and integrated bipolar sensing and pacing in the right ventricle. The performance of the lead was evaluated in 57 patients (age 61 +/- 12 years; New York Heart Association 1.9 +/- 0.6, left ventricular ejection fraction 0.38 +/- 0.15) at implant, at prehospital discharge, and during a 1-year follow-up. Sensing and pacing behavior of the lead was evaluated in six different body positions. In four patients, no stable position of the atrial electrode could intraoperatively be found. The intraoperative atrial sensing was 2.3 +/- 1.6 mV and the atrial pacing threshold 0.8 +/- 0.5 V at 0.5 ms. At follow-up, the atrial sensing ranged from 1.5 mV to 2.2 mV and the atrial pacing threshold product from 0.8 to 1.7 V/ms. In 11 patients, an intermittent atrial sensing problem and in 24 patients an atrial pacing dysfunction were observed in at least one body position. In 565 episodes, a sensitivity of 100% and a specificity of 96.5% were found for ventricular arrhythmias. In conclusion, this single pass defibrillation lead performed well as a VDD lead and for dual chamber arrhythmia discrimination. However, loss of atrial capture in 45% of patients preclude its use in patients depending on atrial pacing.     

The importance of ventricular septal morphology in the effectiveness of dual chamber pacing in hypertrophic obstructive cardiomyopathy

It has been reported that older patients with hypertrophic obstructive cardiomyopathy (HOCM) benefited the most from dual chamber (DDD) pacing. Since in older patients the distribution of septal hypertrophy and left ventricular (LV) cavity shape differs from that in younger patients, we decided to study the efficacy of DDD pacing on the reduction of LV outflow tract (LVOT) gradient in different patterns of septal hypertrophy. We compared HOCM patients with nonreversed septal curvature, thus preserving the elliptical LV cavity contour (common in the elderly), (group I) versus patients with reversed septal curvature, deforming the LV cavity to a crescent shape (common in the young), (group II). Eighteen HOCM patients were studied (11 patients in group I and 7 patients in group II). After implantation of a DDD pacemaker, the LVOT gradient was measured using Doppler echocardiography at various programmed AV delay intervals to determine the maximal percentage decrease of LVOT gradient from baseline. The measurement was repeated after at least a 6-month follow-up (chronic DDD pacing). The baseline LVOT gradient was comparable between groups (79 +/- 28 vs 81 +/- 25 mmHg, P = 0.92). The LVOT gradient reduction at acute DDD pacing was significantly greater in group I than group II (61 +/- 18% vs 23 +/- 10%, P = 0.0001). This difference in favor of the patients from group I was maintained at midterm follow-up (69 +/- 17% vs 40 +/- 17% P = 0.0076). In conclusion, patients with normal septal curvature and preserved elliptical LV cavity shape had a greater reduction of LVOT gradient after DDD pacing than patients with reversed septal curvature deforming LV cavity. The proposed criterion assessing the septal curvature may be useful to predict the efficacy of DDD pacing in the reduction of LVOT gradient.     

Age dependency of sensing performance and AV synchrony in single lead VDD pacing

Implantation of single lead VDD pacemakers is an established therapeutic option in patients with AV block and normal sinus node function. However, related to occurrence of sinus node disease and atrial undersensing, there is concern whether VDD devices are appropriate in physically active young patients. Two hundred thirty-two consecutive patients with isolated AV block and VDD pacemakers were investigated. This population was subdivided into quartiles of 58 patients according to age at time of inclusion: 26.2-59.4 years (group A), 59.5-70.1 years (group B), 70.2-81.0 years (group C), and 81.1-92.5 years (group D). Follow-up visits included pacemaker telemetry, Holter monitoring, and exercise testing. Patients were visited at 2 and 12 weeks after implantation thereafter followed by 6-month intervals. Mean follow-up period was 35 +/- 14 months. Three months after implantation, atrial sensing threshold was significantly higher in young patients: 1.18 +/- 0.58 mV (group A) versus 0.79 +/- 0.35 mV (group B), 0.68 +/- 0.33 mV (group C), and 0.60 +/- 0.25 mV (group D), P < 0.001 for comparison of group A to all other groups. Atrial undersensing was observed less frequently in young patients: 6.9% (group A) versus 17.2% (group B), 24.1% (group C), and 27.6% (group D), P = 0.025 for intergroup comparisons. Sinus node dysfunction did not occur in group A. Atrial arrhythmias and loss of AV synchronized pacing mode occurred rarely in young patients: 0.6% (0.4%) per year in group A versus 1.3% (1.3%) in group B, 3.9% (3.4%) in group C, and 5.7% (7.4%) per year in group D, P < 0.01 for intergroup comparisons. Our data show good atrial sensing performance, low incidence of sinus node dysfunction, and few atrial arrhythmias in young patients with VDD pacing for AV block. Thus, single lead VDD pacing can be recommended particularly for young patients with AV block.     

Long-Term Follow-Up of Patients with Single Lead VDD Stimulation

The purpose of this study was to assess the long-term results of a single lead VDD pacing system (Phymos MPS) in 85 patients (48 males, 37 females, mean age 74 ± 9 years). The system, which incorporates two atrial floating electrodes (Phymos 830-S). was implanted for second- or third-degree Mobitz II AV block. The percentage of AV synchronized pacing, the presence of fusion beats due to short AV delay, and the occurrence of supraventricuiar arrhythmias was evaluated by Holter monitoring at 6-month intervals. Over a mean period of follow-up of 44 months (range 2–56), over 90% of AV synchronized pacing events were noted in 74 patients (87%). The presence of persistent fusion beats was detected in 12 patients (14%). In ten patients the pacemaker was reprogrammed to VVI mode for supraventricuiar arrhythmias (7 patients, 8.2%) or unsatisfactory atrial sensing (3 patients, 3.5%). One pacemaker was removed for pocket infection and two for battery depletion. These observations support the use of VDD single lead pacing to combine a physiological mode of stimulation with simple implantation techniques.     

Chronic experiences with a single lead dual chamber implantable cardioverter defibrillator system

Monitoring of atrial rhythm in patients implanted with ICDs may improve accuracy in identifying supraventricular arrhythmias and, therefore, prevent inappropriate therapies. Since difficulties were found in dual chamber ICDs with separate leads, a new designed single lead dual chamber ICD system was tested. Twenty-five patients implanted with a Deikos A+ (single coil defibrillation lead with two atrial sensing rings combined with a dual chamber ICD with a high amplifying atrial channel) were tested. Atrial and ventricular signals were analyzed during sinus rhythm (SR) and sinus tachycardias (STs), atrial flutter and AF, and VT or VF. Follow-ups were performed after 1, 3, 6, 9, and 12 months after implantation. Analysis of EGM amplitudes of stored episodes revealed that atrial signals during atrial flutter (2.1 +/- 0.51 mV) were comparable to those of ST (2.2 +/- 0.5 mV). Atrial amplitudes during AF were significantly lower (0.81 +/- 0.5 mV, P<0.01). During VF atrial "sinus" signals (2 +/- 0.8 mV) were stable. Ventricular parameters did not differ from a standard ICD lead; defibrillation threshold was 11.4 +/- 4.5 J (16 patients). During intraoperative and prehospital discharge measurements, 97.1% of SR-P waves and 99.2% of atrial flutter waves were detected correctly. In AF 91.11% of atrial signals were detected. Analysis of 505 stored episodes showed that 96.8% of ST and 100% of atrial flutter and 100% of AF episodes have been classified correctly and no underdetection of VT/VF was found. The first experiences with the new VDD-ICD system show an increase of the specificity to detect ventricular tachycardias to a level comparable to dual chamber ICDs with two leads. The reliability of this system has to be proven in a prospective randomized study.     

Single Pass VDD Pacing in Children and Adolescents

Use of a single pass lead for VDD pacing in complete heart block is well described in adults, but there are only brief reports of its use in children. We have used standard adult size single pass leads in 13 children and adolescents aged 3.7–17.2 years (mean 10.1 years) and weighing 13.5–76 kg (mean 34.8 kg). Congenital complete heart block was present in 7 patients, surgical complete heart block in 5 patients and 2:1 AV block of unknown cause in 1 patient. In four patients, the VDD system was their first pacing system. In nine of the patients, 1–6 previous systems had been used and simultaneous extraction of ventricular leads and/or atrial leads was performed. Leads of four different types were used: Brilliant IMPl5Q, Brilliant + IMR15Q, CapSure 5032, and Unipass 425–13 with 4 different generators: Saphir 600, SaphirII620, Thera VDD 8948, and Unity 292–07. At implantation, via a subclavian vein puncture, excess lead was advanced into the right atrium to allow both atrial sensing and slack for further growth. Ventricular thresholds ranged from 0.2–0.7 V. The minimal atrial amplitude was 0.7–4 mV and the maximum amplitude was 2.5–8 mV. There were no complications. Ail patients have maintained adequate atrial signals for reliable pacing with follow up of 3–36 months (mean 17.6 months) during which time some have undergone considerable growth. Beliable atrial synchronous ventricular pacing is possible in growing children with complete heart block using a standard adult single pass lead.     

Single Pass Lead VDD Pacing in Children and Adolescents

Implantation of permanent pacemakers in children and adolescents is possible but usually is limited to single chamber generators. The natural growth of these patients may require physiological pacing, but until recently two leads were required for this type of pacing. The single pass lead VDD pacing mode makes posible physiological pacing by using only one lead, for both atrial sensing and ventricular sensing and pacing. The feasibility of VDD pacing using endocardial lead was evaluated in 16 children and adolescents with congenital or postsurgical atrioventricular block. Their mean age was 7.9 ± 4.9 years (range 1-16 years) and the smallest patient's weight was 8.2 kg. In all the patients, a single pass pacing lead with atrial sensing rings and bipolar ventricular pacing and sensing capability was implanted through the left or right subclavian vein. The pacemaker generator was implanted in a rectopectoral position. The mean atrial electrogram during the implantation was 4.2 ± 2.1 mV and 2.6 ± 1.9 mV after a mean of 1 week. The ventricular pacing threshold was 0.5 ± 0.2 V; the ventricular pacing impedance was 560 ± 95 Ω and the ventricular electrogram amplitude was 9.9 ± 2.1 mV. This is a first report to demonstrate the feasibility of atrial synchronous ventricular endocardial pacing using a single pass lead in a relatively large group of children and adolescents.     

Dual demand pacing using retriggerable refractory periods for ventricular rate control during paroxysmal supraventricular tachyarrhythmias in patients with dual chamber pacemakers

The use of dual chamber pacing in patients with atrioventricular block and paroxysmal supraventricular tachyarrhythmias may present a clinical dilemma because of the rapid and erratic triggering of ventricular pacing. To avoid this, a variety of pacing methods have now been described, including the use of retriggerable atrial refractory periods or dual demand pacing. This review details the use, advantages, and limitations of this poorly understood algorithm referred to as "pseudo-mode switching."     

Upgrading of VVIR pacemakers with nonfunctional endocardial ventricular leads to VDD pacemakers in adolescents

Background: In some children with ventricular rate responsive demand (VVIR) pacemakers (PM), transvenous leads fail for technical reasons or patient's growth.
Aim: The aim of this study is to describe our experience in adolescents with a nonfunctional ventricular lead in whom the lead was abandoned and an additional VDD lead was implanted. Of the 136 children who received a VVIR PM with an endocardial lead in our center, seven patients aged 7 (0.3–12) years [median (range)] at initial implantation, after 10 (5–15) years showed lead malfunction and underwent atrial synchronous ventricular inhibited pacing (VDD) PM upgrading at 16 (10–20) years.
Results: The VDD lead was inserted through the ipsilateral subclavian vein in five patients, the contralateral in two (venous occlusion in one and for operator choice in the first patient). The tip was positioned into the right ventricular apex, the atrial dipole along the lateral atrial wall. Fluoroscopy times were not significantly different from those measured in SSI PM implantation and in VVIR dual-chamber demand pacing (VVIR-DDD) upgrading. There were no intraprocedural complications. Follow-up duration is 12 (6–62) months. The VDD PM showed good function, no undersensing or oversensing. Tricuspid damage, new venous occlusion, and "twisting" of the two leads at x-ray were not documented. The first patient showed an infection of the old PM pocket after 1 year, local pain after 3 years, and endocarditis of the leads after 5 years.
Conclusion: The upgrading of VVIR PM to VDD PM with the abandonment of the nonfunctional lead is feasible, with no intraprocedural complications and good PM function. Lead endocarditis occurred in one patient.     

Single Lead VDD Pacing: Multicenter Study

Optimal treatment for patients with AV block and normal sinoatrial node (SA) function entails atrial sensing and ventricular pacing (VDD mode). Single-lead VDD pacing preserves AV synchrony, precludes the need to insert two leads, and makes the implanter's work simpler and quicker. Our objectives were to verify the performance of the Thera(tm) VDD pacing system (Medtronic, Inc., Minneapolis, MN, USA), and evaluate the effectiveness of its atrial sensing and its ventricular sensing and pacing. In 165 patients, 150 adults (mean age 62 ± 18 years) and 15 children (mean age 7 ± 5 years) with 1°–3° AV block and normal SA node function, a Thera VDD system (Models 8948 or 8968) was implanted. Intraoperative ventricular electrical measurements were not significantly different from those of VVI pacemakers. The mean amplitude of the atrial signal during implantation was 4.1 ± 1.9 mV. Optimal atrial signals during implantation were usually obtained in the mid or lower part of the right atrium by using a special technique. Adequate atrial measurements remained stable throughout 24 months. There was no difference between serial measurements of atrial signal amplitudes at predischarge and during follow-up visits. Reposition of the lead was done in 2 patients (1.4%), and reprogramming to VVI in 7 patients: due to atrial fibrillation in 3 (1.8%) and due to atrial undersensing in 4 patients (2.4%). Thera VDD pacing is reliable and easy to manage with dependable atrial sensing and ventricular pacing. The survival rate of VDD pacing at 2 years was 96%.     

Clinical Evaluation of a New Single Pass Lead VDD Pacing System

Twenty-five patients with second- to third-degree AV block and normal sinus function (16 males, mean age 60 ± 18; range 15–78 years) underwent implantation of WD pacemakers (THERA VDD, Medtronic, Inc.) with a single pass (SP) lead. Results: During implantation the mean amplitude of the atrial (A) signal was 3.9 ±1.4 mV (range 2.0–7.8 mV). Stable, acceptable A-signals during implantation were usually observed in the mid- or lower part of the right atrium. The lead tip electrical parameters were not compro mised in any patient in order to obtain an acceptable A-signal. To verify VDD device function, patients underwent pacing system analysis on the second day and again 1, 3, and 6 months after implantation. Acute and chronic electrical measurements in the ventricle were similar to those with regular steroid leads. During follow-up tests, stable atrial sensing (A ≥ 0.7mV) was found in all but one patient (in whom A was 0.25–0.5 mV and an intermittent loss of atriai sensing occurred). There was no difference between serial measurements of A-signal amplitudes on the second day or 1, 3, and 6 months after implantation: 1.9 ± 1.3 mV, 1.5 ± 0.6 mV, 1.3 ± 0.8 mV, and 1.5 ± 1.1 mV, respectively. The mean implantation time was 54.0 ± 17 minutes and the mean fluoroscopy time was 3.2 ±1.3 minutes. Conclusions: SP lead VDD pacing is reliable and easy to manage with dependable atriai sensing and ventricular pacing. The significant reduction in atriai postimplantation amplitude is related to the different techniques used for measuring acute and chronic atriai signals.     

VDD Single Pass Lead Pacing; Sustained Pacemaker Mediated Tachycardias Unrelated to Retrograde Atrial Activation

Pacemaker mediated tachycardias (PMTs) are a well known complication of P synchronous pacing. Although the initiating mechanisms are severel, all of them are associated with retrograde atrial activation, which is sensed by the atrial sensing channel, resulting in ventricular pacing. In 19 patients suffering from symptomatic AV conduction disturbances and normal sinus node function, a VDD pacing system connected to a single pass ventricular lead with dual chamber electrodes was implanted. The bipolar atrial electrode, floating in the right atrium, was used to detect endocardial atrial electrograms that were differentially processed within the pacemaker for optimal discrimination and filtering of undesirable signals. The widely programmable atrial sensitivity (amplitude and filtering) allowed stable P synchronized ventricular pacing in all patients, but in five of them, sustained PMTs not related to retrograde atrial activation was documented during the follow-up. The common mechanism for the onset and maintenance of these PMTs was traced to the abnormal sensing of the terminal forces of ventricular activation and for of the T wave. The possibility of interferences between ventricular and atrial electrodes (crosstalk) was also considered, The reduction of atrial channel sensitivity represented in all cases the only effective procedure to prevent this type of PMT. In conclusion, the best signal to noise ratio is an important endpoint (o assure the proper function of a single lead VDD pacing system. Furthermore, using the differential amplifier built within the pacemaker, consideration should be given to the optimal mode of rejection of the terminal forces of the QRS and T wave.     

Development of an echocardiographic method for choosing the best fitting single-pass VDD lead

To achieve stable single-lead VDD pacing, a selection of the electrode with the optimal distance between the lead tip and the floating atrial dipole (AV distance [AVD]) is important. The authors hypothesized that the size of the right heart chambers may affect atrial sensing, and that measurement of their internal dimension at end-diastole (RHIDd) in the apical four chamber view by transthoracic echocardiography may aid in choosing the proper AVD. Twenty-six consecutive cases that had undergone VDD pacer implantation using the conventional chest X ray were examined retrospectively by the echocardiographic method. The chest x-ray method properly selected a lead with optimal atrial sensing, defined as minimum P wave amplitude > or = 1.0 mV, for only 20 (77%) of 26 patients. By comparing these results with their respective RHIDd, a cut-off point of 13 cm was obtained that indicated a criterion for choosing the proper AVD. The indication was that if the RHIDd was > or = 13 cm, a lead with an AVD of 15.5/16 cm should have been used; if the RHIDd was < 13 cm, a lead with an AVD of 13/13.5 cm should have been chosen. Using the echocardiographic method, all six patients who had suboptimal atrial sensing could be identified and classified as having missized (four undersized; two oversized) permanent leads. In conclusion, the described method provides a promising preoperative assessment of the best fitting electrode length in single lead VDD pacing. A prospective study is ongoing to verify its applicability.     

Is There a Risk for Interaction Between Mobile Phones and Single Lead VDD Pacemakers?

Mobile phones may cause pacemaker interference. Patients with a single lead VDD pacemaker might be at special risk, since the atrial sensitivity is often programmed to low (high sensitivity) threshold values and the majority of patients are pacemaker dependent due to the underlying high degree AV block. We evaluated 31 patients with three types of single lead VDD pacemakers: 12 Unity, 292–07 (Intermedics, Inc.); 10 Thera VDD, 8948 or 8968i (Medtronic, Inc.); and 9 Saphir 600 (Vitatron, Inc.) for interference from a cellular mobile phone with a power of 2 W (D-net). For this purpose, atrial and ventricular sensitivity settings were programmed to their most sensitive values (A: 0.1–0.25 mV; V: 1.0 mV) and ventricular sensing was programmed to unipolar. With the ECG continuously monitored, the phone's extendable antenna was brought in direct contact with the patient's skin at the right sternal border, with the tip of the antenna in skin contact just below the clavicle, within 5 cm of the pacemaker connector. Then multiple phases of phone calls were performed, and the effects on the pacemakers recorded. In our group of patients with three different types of single lead VDD pacemakers, no interference could be detected using a 2-W mobile phone in the digital D-net. The programmed values remained unchanged after the interference test. Therefore, the risk of interference seems to be low for the VDD pacemakers tested, although our study design does not allow to entirely exclude the possibility of interference from a mobile phone.